The phrase “gene synthesis companies” covers a surprisingly wide field. Some of these businesses write DNA, some read it, and some build the software that tells the rest of the lab what to do. Adam O’Dell, the chief investment strategist at Money & Markets, builds his “Imperium” pitch around a small cluster of them, and the way he sorts them is worth understanding before you look at any single ticker. He groups the whole synthetic-biology industry into a three-layer stack borrowed from the personal-computer era, and each layer points at a specific company.

The Write Layer: Twist Bioscience (TWST)

Twist Bioscience (TWST) is the “silicon layer” of the pitch, the Intel of the DNA revolution in O’Dell’s framing. The company makes synthetic DNA, and its differentiator is how. Twist’s NanoWell technology synthesizes DNA on silicon chips instead of in test tubes, an approach the presentation says “processes DNA at 10,000 times the speed of the previous technology.” That 10,000-times figure is a marketing number our analysis could not independently verify, but the direction is real: writing DNA keeps getting faster and cheaper.

Twist’s customer list gives the claim some weight. Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA all show up as partners or customers. The business has posted 15 consecutive quarters of revenue growth at roughly 20% a year, carries a market cap near $7.6 billion, and sits close to break-even on an adjusted cash-flow basis, with analysts modeling about $1.50 in adjusted earnings per share by fiscal 2028. O’Dell teased the stock around $112, matching the November 17 close. For the fuller bull and bear case, see our Twist Bioscience stock piece.

The Software Layer: Ginkgo Bioworks (DNA)

Ginkgo Bioworks (DNA) is the “software layer,” the Microsoft of the stack. Founded by five MIT PhDs, Ginkgo was briefly worth around $20 billion at its 2021 SPAC-era peak and is now worth roughly $539 million, one of the sharper drawdowns of that boom. The business has changed course since. Instead of selling custom molecules, the original “foundry” plan, Ginkgo now sells autonomous “DNA factories,” robotic lab equipment that runs DNA-driven experiments for AI and pharma companies. Its first such sale went to Novo Nordisk, and it has new government wins with ARPA-H and the NSF.

The Microsoft label comes from a 2015 quote from Twist’s own chief executive: “We’re Intel, they’re Microsoft.” It is a memorable line, though Ginkgo’s business model today looks quite different from the one the quote described. We walk through that history in our Ginkgo Bioworks stock piece.

A Nearby Corner: Codexis (CDXS)

Codexis (CDXS) sits in a nearby corner of the same field. Where Twist writes DNA and Ginkgo builds the robotic labs, Codexis engineers enzymes, the proteins that drive chemical reactions. Enzymes are the workhorses behind a lot of pharmaceutical and industrial manufacturing, and Codexis has spent years refining a platform for designing and evolving them for specific jobs. It is a useful reminder that “synthetic biology” is not one market but a family of them, and that the companies inside it sell different things to different buyers.

The Equipment Layer

O’Dell’s analysis also names the companies that sell the broader equipment these firms depend on. Illumina, Thermo Fisher, and Danaher compete at the equipment layer, selling the sequencers, reagents, and lab instruments that read and handle DNA. These are the incumbents, far larger and more diversified than the synthetic-biology upstarts, and they are the names that show up whenever anyone asks who else is in the room.

How the Thesis Ties Them Together

The point of the Imperium pitch is that these companies together form a stack, and that the stack is about to go mainstream. O’Dell’s framing is memorable: “Once you can read, design, and write the code of living things, every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.” His record gives the framing some credibility. He began teasing Palantir in the spring of 2024 when the stock was in the $20s, and it became the best-performing stock in the S&P 500 for that year.

The honest read is that these are three different companies with three different risk profiles, not one interchangeable bet. The market for writing DNA is real and growing, and the drivers are covered in our gene synthesis market piece.

Why the Pitch Keeps Returning

O’Dell has been running some version of this theme since February 2021, when he first teased Twist in the $120s. He swapped the pick for Pacific Biosciences in the spring of 2024, a call that never worked out, and has now come back to Twist for the 2027 edition. That history does not make the current picks wrong, but it is a reminder that the companies under the story have shifted over the years even as the story itself, that DNA is becoming software, has stayed the same.

The Offer and the Presenter

The subscription that carries these names is “Imperium: The No. 1 Investment for 2027,” priced at $297 a year with a 30-day refund. For that you get the Green Zone Fortunes service itself plus the special reports that name Twist, Ginkgo, and Absci. O’Dell also runs two related services, Cycle 9 Alert and 10X Profits, and his signature tool is the Green Zone Power Ratings, a quantitative screen that scores stocks on momentum, value, and volatility, then sorts them into buy and sell zones. That discipline is a real framework, and it gives his recommendations a consistency many newsletter pitches lack.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.